Cargando…

Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients

Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Million, Matthieu, Lagier, Jean-Christophe, Hourdain, Jérôme, Franceschi, Frédéric, Deharo, Jean-Claude, Parola, Philippe, Brouqui, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220868/ https://www.ncbi.nlm.nih.gov/pubmed/37241095 http://dx.doi.org/10.3390/medicina59050863

Ejemplares similares

Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis
por: Lagier, Jean-Christophe, et al.
Publicado: (2022)

Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
por: Million, Matthieu, et al.
Publicado: (2021)

Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients
por: Brouqui, Philippe, et al.
Publicado: (2023)

Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity
por: Hache, Guillaume, et al.
Publicado: (2021)

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
por: Lagier, Jean-Christophe, et al.
Publicado: (2020)

SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment
por: Drancourt, Michel, et al.
Publicado: (2021)

WITHDRAWN: Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
por: Million, Matthieu, et al.
Publicado: (2021)

Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
por: Gautret, Philippe, et al.
Publicado: (2021)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Million, Matthieu, et al.
Publicado: (2021)

Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
por: Gautret, Philippe, et al.
Publicado: (2021)

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
por: Million, Matthieu, et al.
Publicado: (2020)

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
por: Gautret, Philippe, et al.
Publicado: (2020)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
por: Gautret, Philippe, et al.
Publicado: (2020)

Asymptomatic hypoxia in COVID-19 is associated with poor outcome
por: Brouqui, Philippe, et al.
Publicado: (2021)

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
por: Colson, Philippe, et al.
Publicado: (2020)

Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study
por: Maille, Baptiste, et al.
Publicado: (2021)

Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
por: Gautret, Philippe, et al.
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
por: Million, Matthieu, et al.
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes
por: Gautret, Philippe, et al.
Publicado: (2021)

Diaphragmatic CMAP Monitoring During Cryoballoon Procedures: Surface vs. Hepatic Recording Comparison and Limitations of This Approach
por: Tovmassian, Lilith, et al.
Publicado: (2022)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
por: Osman, Ikram Omar, et al.
Publicado: (2021)

Hydroxychloroquine + azithromycin treatment in elderly patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Advantages and disadvantages of drug challenge during electrophysiological study in patients with new left bundle branch block after transaortic valve implantation
por: Maille, Baptiste, et al.
Publicado: (2022)

Low-dose chest CT for diagnosing and assessing the extent of lung involvement of SARS-CoV-2 pneumonia using a semi quantitative score
por: Leger, Thomas, et al.
Publicado: (2020)

Olfactory and gustative disorders for the diagnosis of COVID-19
por: Boudjema, Sophia, et al.
Publicado: (2020)

Life-years lost by COVID-19 patients in public hospitals of Marseille (APHM-South-Eastern France): a limited death toll: a retrospective analysis
por: Arlotto, Sylvie, et al.
Publicado: (2021)

Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
por: Castelli, Maxime, et al.
Publicado: (2020)

Correction to: Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
por: Castelli, Maxime, et al.
Publicado: (2021)

Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection
por: Voisin, Olivier, et al.
Publicado: (2020)

Infections in symptomatic travelers returning from the Arabian peninsula to France: A retrospective cross-sectional study
por: Griffiths, Karolina, et al.
Publicado: (2016)

Thromboses in tuberculosis are linked to antiphosphatidylethanolamine antibodies levels: A cross-sectional study
por: Bessis, Simon, et al.
Publicado: (2019)

Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do not exhibit greater viral loads than adults
por: Colson, Philippe, et al.
Publicado: (2020)

Lack of MERS Coronavirus but Prevalence of Influenza Virus in French Pilgrims after 2013 Hajj
por: Gautret, Philippe, et al.
Publicado: (2014)

Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France
por: Hoang, Van-Thuan, et al.
Publicado: (2021)

Triangular test applied to the clinical trial of azithromycin against relapses in Plasmodium vivax infections
por: Ranque, Stéphane, et al.
Publicado: (2002)

Claims about the safety and efficacy of early treatment of COVID-19 with hydroxychloroquine and azithromycin must be supported by real evidence
por: Bigna, Jean Joel, et al.
Publicado: (2020)

Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients
por: Honoré, Stéphane, et al.
Publicado: (2021)

Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
por: Gautret, Philippe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3gogv34fhoe6mdeeedhbp3kguo